CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 241 enrolled
Drug / intervention
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate +2 morebiological
Likely dose
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00777790
NCT00777790Phase 2Completed
CompareCT.gov

Antibody Responses to a Booster Dose of an Experimental Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine, Menactra® in Adolescents Who Previously Received Menomune® or Menactra®

Sanofi Pasteur, a Sanofi Company·interventional·Posted Oct 22, 2008·Updated Feb 14, 2014

In Brief

A Phase 2 clinical trial evaluating Meningococcal Polysaccharide Diphtheria Toxoid Conjugate for Meningitis and Meningococcemia. Completed, enrolled 241 participants across 9 sites.

Detailed Summary

This study was designed to evaluate the antibody response to a Menactra® booster dose in participants who previously received one dose of Menactra® or Menomune® as adolescents 3 years earlier in Study MTA02. Primary Objective: To evaluate the antibody responses to a booster dose of a tetravalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) in participants who had previously received Menactra® or Menomune® as adolescents in the MTA02 Study and antibody responses to a dose of Menactra® in naive adolescents.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeningitis, Meningococcemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 22, 2008
Enrollment StartFeb 1, 2004
Primary CompletionApr 1, 2004
Study CompletionApr 1, 2005
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 17.7 years ago

Interventions

Meningococcal Polysaccharide Diphtheria Toxoid Conjugatebiological

0.5 mL, Intramuscular

Meningococcal Polysaccharide Diphtheria Toxoid Conjugatebiological

0.5 mL, Intramuscular

Meningococcal Polysaccharide Diphtheria Toxoid Conjugatebiological

0.5 mL, Intramuscular